WO2024261237 - FLUOROMETHYL-CARNITINE FOR USE AS A CHOLINE TRIMETHYLAMINE (TMA) LYASE INHIBITOR
National phase entry is expected:
Publication Number
WO/2024/261237
Publication Date
26.12.2024
International Application No.
PCT/EP2024/067429
International Filing Date
21.06.2024
Title **
[English]
FLUOROMETHYL-CARNITINE FOR USE AS A CHOLINE TRIMETHYLAMINE (TMA) LYASE INHIBITOR
[French]
FLUOROMÉTHYL-CARNITINE DESTINÉE À ÊTRE UTILISÉE COMME INHIBITEUR DE LA CHOLINE TRIMÉTHYLAMINE (TMA) LYASE
Applicants **
ALFASIGMA S.P.A.
Inventors
GIANNINI, Giuseppe
BATTISTUZZI, Gianfranco
TADDEI, Maurizio
CINI, Elena
Priority Data
102023000012522
22.06.2023
IT
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2385 | |
| EPO | Filing, Examination, Granting | 11650 | |
| Japan | Filing, Examination, Granting | 2356 | |
| South Korea | Filing, Examination, Granting | 2303 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
23,434
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention relates to a compound of formula (I) for use in the treatment of disorders and/or conditions associated with high trimethylamine (TMA) and/or trimethylamine N-oxide (TMAO) plasma levels, or for use in the treatment of disorders and/or conditions associated with a high ratio of TMA/TMAO plasma concentrations as well as relative composition and method of preparation.[French]
La présente invention concerne un composé de formule (I) destiné à être utilisé dans le traitement de troubles et/ou d'états pathologiques associés à des taux plasmatiques élevés de triméthylamine (TMA) et/ou de N-oxyde de triméthylamine (TMAO), ou destiné à être utilisé dans le traitement de troubles et/ou d'états pathologiques associés à un rapport élevé de concentrations plasmatiques de TMA/TMAO, ainsi qu'une composition et un procédé de préparation correspondants.